Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor in Primary Sclerosing Cholangitis
NCT07387549Phase 3Recruiting
- Sponsor
- Ipsen
- Start
- May 2026
- Primary completion
- Apr 2031
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of elafibranor in Primary Sclerosing Cholangitis (PSC), sponsored by Ipsen. Started May 2026; status: recruiting.
02
Drugs
elafibranor
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT07387549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07387549.